A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Gotham Asset Management, LLC holds 36,440 shares of DVAX stock, worth $447,847. This represents 0.01% of its overall portfolio holdings.

Number of Shares
36,440
Previous 70,853 48.57%
Holding current value
$447,847
Previous $879,000 53.47%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.73 - $12.58 $369,251 - $432,915
-34,413 Reduced 48.57%
36,440 $409,000
Q1 2024

May 15, 2024

BUY
$11.7 - $14.98 $209,102 - $267,722
17,872 Added 33.73%
70,853 $879,000
Q4 2023

Feb 14, 2024

SELL
$13.09 - $14.98 $15,459 - $17,691
-1,181 Reduced 2.18%
52,981 $740,000
Q3 2023

Nov 14, 2023

SELL
$12.64 - $14.99 $6,699 - $7,944
-530 Reduced 0.97%
54,162 $799,000
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.17 $770,506 - $1.03 Million
-78,224 Reduced 58.85%
54,692 $706,000
Q1 2023

May 15, 2023

SELL
$9.44 - $11.88 $1.03 Million - $1.3 Million
-109,472 Reduced 45.16%
132,916 $1.3 Million
Q4 2022

Feb 14, 2023

BUY
$10.27 - $13.29 $759,733 - $983,141
73,976 Added 43.93%
242,388 $2.58 Million
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $1.09 Million - $1.92 Million
109,810 Added 187.38%
168,412 $1.76 Million
Q2 2022

Aug 15, 2022

SELL
$7.45 - $12.83 $219,991 - $378,857
-29,529 Reduced 33.51%
58,602 $738,000
Q1 2022

May 16, 2022

BUY
$9.75 - $14.44 $442,094 - $654,752
45,343 Added 105.97%
88,131 $955,000
Q4 2021

Feb 14, 2022

SELL
$13.17 - $20.94 $108,046 - $171,791
-8,204 Reduced 16.09%
42,788 $602,000
Q3 2021

Nov 15, 2021

BUY
$9.16 - $19.83 $467,086 - $1.01 Million
50,992 New
50,992 $980,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.55B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.